TP53对接受造血干细胞移植的骨髓纤维化患者结局的影响
这项国际多中心队列纳入349例接受造血干细胞移植的骨髓纤维化患者,49例(13%)可检测到TP53突变,其中30例为多打击构型。TP53突变患者中位生存1.5年,野生型为13.5年(P < .001);多打击TP53突变6年生存25%,单打击56%,野生型64%。
要点
- 349例中49例(13%)有TP53突变,30例为多打击构型,中位变异等位基因频率20.3%。
- TP53突变中位生存1.5年 vs 野生型13.5年(P < .001),多打击6年生存25% vs 单打击56% vs 野生型64%。
- 多打击TP53突变累积复发率52%,单打击17%,野生型21%;白血病转化多打击8例、单打击2例。
核心结论
- 多打击TP53突变是接受造血干细胞移植的骨髓纤维化患者的极高危组,而单打击TP53突变患者结局与TP53未突变患者相似。
- 上述结果结合现有移植特异性工具,有助于对生存和复发进行预后判断。
研究设计与样本
- 国际多中心队列研究,纳入349例接受造血干细胞移植的骨髓纤维化患者。
- 49例(13%)可检测到TP53突变,其中30例为多打击构型,中位变异等位基因频率为20.3%。
主要发现
- TP53突变患者中位生存1.5年 vs TP53野生型13.5年(P < .001)。
- 6年生存率:单打击TP53突变56% vs 多打击25% vs TP53野生型64%(P < .001)。
- 累积复发率:单打击17% vs 多打击52% vs TP53野生型21%。
- 白血病转化:TP53突变组10例(20%) vs TP53野生型组7例(2%)(P < .001);10例中8例为多打击构型。
- 至白血病转化中位时间:多打击0.7年、单打击0.5年 vs TP53野生型2.5年。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
TP53 mutations (TP53MTs) have been associated with poor outcomes in various hematologic malignancies, but no data exist regarding its role in patients with myelofibrosis undergoing hematopoietic stem cell transplantation (HSCT). Here, we took advantage of a large international multicenter cohort to evaluate the role of TP53MT in this setting. Among 349 included patients, 49 (13%) had detectable TP53MT, of whom 30 showed a multihit configuration. Median variant allele frequency was 20.3%. Cytogenetic risk was favorable (71%), unfavorable (23%), and very high (6%), with complex karyotype present in 36 patients (10%). Median survival of patients with TP53MT was 1.5 vs 13.5 years for those with wild-type TP53 (TP53WT; P < .001). Outcome was driven by multihit TP53MT constellation (P < .001), showing 6-year survival of 56% for individuals with single-hit vs 25% for those with multihit TP53MT vs 64% for those with TP53WT. Outcome was independent of current transplantation-specific risk factors and conditioning intensity. Similarly, cumulative incidence of relapse was 17% for single-hit vs 52% for multihit vs 21% for TP53WT. Ten patients with TP53MT (20%) presented as leukemic transformation vs only 7 (2%) in the TP53WT group (P < .001). Out of the 10 patients with TP53MT, 8 showed multihit constellation. Median time to leukemic transformation was shorter for multihit and single-hit TP53MT (0.7 and 0.5 years, respectively) vs 2.5 years for TP53WT. In summary, multihit TP53MT represents a very high-risk group in patients with myelofibrosis who are undergoing HSCT, whereas single-hit TP53MT alone showed similar outcome to patients with nonmutated TP53, informing prognostication for survival and relapse together with current transplantation-specific tools.
引用
- Gagelmann N, Badbaran A, Salit RB, et al. Impact of TP53 on outcome of patients with myelofibrosis undergoing hematopoietic stem cell transplantation. Blood. 2023. PMID: 36940410. doi:10.1182/blood.2023019630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。